---
title: "Treatment of hepatocellular carcinoma"
date: "2023-02-08"
enableToc: false
---

> [!info]
>
> ğŸŒ± ä¾†è‡ª: [[hepatocellular carcinoma]]

# Treatment of hepatocellular carcinoma

---

![Figure: ](https://i.imgur.com/ofJbB9j.png)

---

(NEJM 2019;380:1450)
[Hepatocellular Carcinoma | NEJM](https://www.nejm.org/doi/full/10.1056/NEJMra1713263)

- Localized disease (goal = cure) â†’ resection if feasible (preferred), ablation, transarterial chemoembolization, or radiotherapy (SBRT) also options. Inadequate hepatic reserve â†’ liver transplant if able (NEJM 1996;334:693); non-surgical local and/or systemic Rx if not.
- Systemic Rx:
  - [[Atezolizumab]] + [[bevacizumab]] preferred (NEJM 2020;382:1894),
  - PD-(L)1 inhib (Lancet 2017;389:2492 & 2018;391:1163)
  - 2nd line: kinase ([[sorafenib]]) or
  - [Sorafenib æŠ—ç™Œè—¥èˆ‡è‡¨åºŠæ‡‰ç”¨](https://www.taiwan-pharma.org.tw/magazine/113/019.pdf)

---

## OS

- First: _Atezolizumab + bevacizumab_ 19.2 months
- First/second Sorafenib: 14.6-10.7 months/
- lenvatinib: 13.7
- 3er: Regorafenib: 10.6 months
- Cabozantinib: 10.2 months
- Ramucirumab (AFP >400): 8.1 months
  (HCC; qv in Heme-Onc) (Nature Reviews 2021;7:6)

- â†‘ risk w/ cirrhosis of any type (leading cause of death in cirrhosis, 1â€“6%/y) but esp. â†‘ w/ viral (Hep B/C~3â€“8%/y), concomitant EtOH use, obesity related NASH, HFE or diabetes

- Clinical: asx vs. hepatic decompensation (eg, ascites, HE), PVT w/ tumor thrombus

- Dx: screen Pts w/ cirrhosis q6mo w/ U/S Â± AFP; alternative is dual-phase CT/MRI

- Rx: see â€œHCCâ€ in Heme-Onc
